Protagonist Therapeutics, Inc.

NASDAQ (USD): Protagonist Therapeutics, Inc. (PTGX)

Last Price

37.58

Today's Change

+0.38 (1.02%)

Day's Change

37.06 - 38.28

Trading Volume

451,751

Overview

Market Cap

2 Billion

Shares Outstanding

59 Million

Avg Volume

697,233

Avg Price (50 Days)

39.82

Avg Price (200 Days)

38.41

PE Ratio

13.72

EPS

2.74

Earnings Announcement

25-Feb-2025

Previous Close

37.20

Open

37.55

Day's Range

37.06 - 38.28

Year Range

24.22 - 48.89

Trading Volume

466,692

Price Change Highlight

1 Day Change

1.02%

5 Day Change

-2.89%

1 Month Change

-5.03%

3 Month Change

-19.63%

6 Month Change

0.59%

Ytd Change

-3.59%

1 Year Change

44.48%

3 Year Change

33.07%

5 Year Change

370.93%

10 Year Change

221.20%

Max Change

221.20%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment